Evidence map›Paper›PMID 37645049›Full record

ArticleArXiv2023

Order-of-mutation effects on cancer progression: models for myeloproliferative neoplasm.

Yue Wang, Blerta Shtylla, Tom Chou

Open access · hybridAbstract readPreprint
In one paragraph

Article in ArXiv, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Yue WangDept. of Computational Medicine, UCLA, Los Angeles, CA 90095.
Blerta ShtyllaMathematics Department, Pomona College, Claremont, CA, 91711.
Tom ChouDept. of Computational Medicine, UCLA, Los Angeles, CA 90095.
Columbia University · USPomona College · USUCLA Health · US

Funding

Tracking clonal dynamics during hematopoiesis: mechanistic insight via modeling and data analysisR01HL146552 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHOU, TOM · 2019 to 2022
$907k
NHLBI NIH HHS R01 HL146552
6 · The paper itself

Abstract

In some patients with myeloproliferative neoplasms (MPN), two genetic mutations are often found, JAK2 V617F and one in the TET2 gene. Whether or not one mutation is present will influence how the other subsequent mutation affects the regulation of gene expression. When both mutations are present, the order of their occurrence has been shown to influence disease progression and prognosis. We propose a nonlinear ordinary differential equation (ODE), Moran process, and Markov chain models to explain the non-additive and non-commutative mutation effects on recent clinical observations of gene expression patterns, proportions of cells with different mutations, and ages at diagnosis of MPN. These observations consistently shape our modeling framework. Our key proposal is that bistability in gene expression provides a natural explanation for many observed order-of-mutation effects. We also propose potential experimental measurements that can be used to confirm or refute predictions of our models.

Indexed as

bistabilitycancergene expressionMoran processmutation order

Identifiers

PMID37645049
PMCPMC10462171
OpenAlexW4386080934

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.